Close Menu

NEW YORK – GeneCentric Therapeutics and the Netherlands-based Erasmus University Medical Center said on Thursday that they are collaborating to identify RNA-based drug response markers and novel, targeted therapies for treating non-muscle invasive bladder cancer (NMIBC).

Under the research collaboration, North Carolina-based GeneCentric will use its Bladder Cancer Subtype Profiler tool to characterize the tumor, the patient's immune biology, and the tumor microenviroment. It may also use other novel assays to predict disease progression and drug response in these patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Sponsored by

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.